U.S. pharmaceutical company Johnson & Johnson (J&J) is conducting clinical trials for its prostate cancer (prostate gland ...

Prostate cancer (PCa) represents a major health burden across Europe, and screening is already widely performed, predominantly through opportunistic PSA ...

A study of 302 patients found prostate artery embolization significantly improved urinary symptoms, objective parameters, and ...

Researchers at Endeavor Health and GoPath Diagnostics have developed a new genetic test that can help predict which men with prostate cancer are most likely to develop aggressive, life-threatening ...

Rodger Allen has been training in sand dunes to prepare for his desert challenge.

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Prostate cancer treatments carry different risks. Dr. Fernando Bianco argues for informed decisions that balance cancer ...

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

Scientists have discovered vital clues to help predict, more than a decade in advance, which men may develop prostate cancer.

C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...